Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2140 plus R-CHP vs polatuzumab vedotin plus R-CHP in treatment-naive GCB DLBCL
jRCT2021250001Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing Zilovertamab vedotin + R-CHP with Polatuzumab vedotin + R-CHP (2 arms). Primary endpoint: Complete response rate at end of treatment. Started Jul 2025; status: recruiting.
02
Drugs
zilovertamab vedotinpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2021250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250001.